This is the first study to demonstrate that the circ-SIRT1/EIF4A3/N-cadherin/vimentin axis promotes the proliferation and EMT of CRC cells, providing a novel therapeutic target and strategy for the treatment of this cancer. Here, EIF4A3 is linked to colorectal carcinoma.